Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Itovebi

(i-TOV-bee)
A drug used with palbociclib and fulvestrant to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer that has a mutation (change) in the PIK3CA gene. It is also being studied in the treatment of other types of cancer. Itovebi works by blocking the activity of a protein called PI3K-alpha that signals cancer cells to multiply. It also helps break down mutant versions of this protein found in some cancer cells. This may keep cancer cells from growing and may kill them. Itovebi is a type of targeted therapy drug called an enzyme inhibitor. Also called inavolisib.
More Information
Search NCI's Dictionary of Cancer Terms